Race Oncology

Historical price data

Racura Oncology is advancing RC220, a reformulated version of the anthracene-based drug (E,E)-bisantrene, through three clinical programs in AML, EGFRm NSCLC, and solid tumors. The company's key innovations include the 2025 discovery of its novel MYC-silencing mechanism, enabling new composition-of-matter patents, and the demonstration of cardioprotection when combined with anthracyclines. Operating with a lean, virtual model, Racura's strategy is to progress its clinical portfolio while actively seeking strategic partnerships or M&A to accelerate global commercialization.

Proprietary small molecule (E,E)-bisantrene that silences the MYC oncogene via G-quadruplex DNA/RNA binding and provides cardioprotection, reformulated as RC220 for peripheral IV administration.

RC220's primary competition in AML includes targeted agents for genetic subsets; its broader mechanism is a differentiator. In solid tumors, its MYC-targeting and cardioprotection are nearly unique, positioning it as a complementary agent to standard chemotherapies rather than a direct competitor to most targeted therapies.